Raltegravir central nervous system tolerability in clinical practice
Authors:
- Giordano MadedduGiordano Madeddu
- Barbara MenzaghiBMBarbara Menzaghi
- Elena RicciERElena Ricci
- Laura CarenziLCLaura Carenzi
- Canio MartinelliCMCanio Martinelli
- Antonio di BiagioABAntonio di Biagio
- Giustino ParrutiGPGiustino Parruti
- Giancarlo OrofinoGOGiancarlo Orofino
- Maria S. MuraMMMaria S. Mura
- Paolo BonfantiPBPaolo Bonfanti
- 28 November 2012
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 26 (18) , 2412-2415
Abstract
Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsClinical Infectious Diseases, 2010
- Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Acute Onset Insomnia Associated with the Initiation of Raltegravir: A Report of Two Cases and Literature ReviewAIDS Patient Care and STDs, 2009
- Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 InfectionPLOS ONE, 2009
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialThe Lancet, 2009
- Raltegravir: The first HIV integrase inhibitorClinical Therapeutics, 2008
- Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase EnzymeDrug Metabolism and Disposition, 2007
- The Hunt for HIV-1 Integrase InhibitorsAIDS Patient Care and STDs, 2006
- Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in CellsScience, 2000